Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.810
+0.070 (4.02%)
Jan 21, 2026, 4:00 PM EST - Market open
Innate Pharma Revenue
Innate Pharma had revenue of 2.43M EUR in the half year ending June 30, 2025, a decrease of -60.63%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.
Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
10.94
Revenue / Employee
69,812 EUR
Employees
181
Market Cap
162.41M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | 85.45M | -8.50M | -9.05% |
| Dec 31, 2018 | 93.95M | 49.92M | 113.37% |
| Dec 31, 2017 | 44.03M | -21.69M | -33.00% |
| Dec 31, 2016 | 65.72M | 40.58M | 161.41% |
| Dec 31, 2015 | 25.14M | 17.52M | 229.80% |
| Dec 31, 2014 | 7.62M | -9.03M | -54.22% |
| Dec 31, 2013 | 16.65M | 2.37M | 16.59% |
| Dec 31, 2012 | 14.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Century Therapeutics | 113.34M |
| Protalix BioTherapeutics | 61.84M |
| ProQR Therapeutics | 18.86M |
| Opus Genetics | 14.63M |
| Surrozen | 3.60M |
| Rani Therapeutics Holdings | 1.20M |
| NeOnc Technologies Holdings | 59.99K |
IPHA News
- 15 days ago - Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 - Business Wire
- 4 weeks ago - Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 - Business Wire
- 6 weeks ago - Innate Pharma Releases Its 2026 Financial Calendar - Business Wire
- 7 weeks ago - Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 - Business Wire
- 2 months ago - Innate Pharma to Present at Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
- 2 months ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Business Wire